Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: A report of 12 cases

被引:90
作者
Coghlan, ME
Sommadossi, JP
Jhala, NC
Many, WJ
Saag, MS
Johnson, VA
机构
[1] Univ Alabama, Sch Med, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA
[2] Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Birmingham, AL USA
[3] Univ Alabama, Sch Med, Dept Anat Pathol, Birmingham, AL USA
[4] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA
关键词
D O I
10.1086/323783
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We retrospectively investigated the clinical and histopathologic features of hospitalized patients infected with human immunodeficiency virus who had symptomatic lactic acidosis syndrome at a university teaching hospital during 1995-2000. Twelve patients were identified, 11 during 1998-2000; of these, 5 died with rapid progression to otherwise unexplained multiple-organ failure. All had extensive prior exposure to nucleoside analog reverse-transcriptase inhibitors (NRTIs). At presentation, the most commonly identified NRTI component of antiretroviral regimens was stavudine plus didanosine. Eleven patients presented with abdominal pain, nausea, and/or emesis. Eight patients had prior acute weight loss (mean [+/- SD],12 +/- 5.3 kg). Median venous plasma lactate levels were greater than or equal to2-fold greater than the upper limit of normal (2.1 mmol/L). Serum transaminase levels were near normal limits at presentation. Histopathologic studies confirmed hepatic macrovesicular and microvesicular steatosis in 6 patients. Concurrent chemical pancreatitis was identified in 6 patients. The increasing number of cases identified during the study period suggests that physicians better recognize symptomatic lactic acidosis and/or that cumulative NRTI exposure may increase the risk for this syndrome.
引用
收藏
页码:1914 / 1921
页数:8
相关论文
共 26 条
  • [1] FULMINANT-HEPATITIS WITH SEVERE LACTATE ACIDOSIS IN HIV-INFECTED PATIENTS ON DIDANOSINE THERAPY
    BISSUEL, F
    BRUNEEL, F
    HABERSETZER, F
    CHASSARD, D
    COTTE, L
    CHEVALLIER, M
    BERNUAU, J
    LUCET, JC
    TREPO, C
    [J]. JOURNAL OF INTERNAL MEDICINE, 1994, 235 (04) : 367 - 371
  • [2] Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
    Brinkman, K
    ter Hofstede, HJM
    Burger, DM
    Smeitinkt, JAM
    Koopmans, PP
    [J]. AIDS, 1998, 12 (14) : 1735 - 1744
  • [3] A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome
    Carr, A
    Miller, J
    Law, M
    Cooper, DA
    [J]. AIDS, 2000, 14 (03) : F25 - F32
  • [4] Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion
    Chariot, P
    Drogou, I
    de Lacroix-Szmania, I
    Eliezer-Vanerot, MC
    Chazaud, B
    Lombès, A
    Schaeffer, A
    Zafrani, ES
    [J]. JOURNAL OF HEPATOLOGY, 1999, 30 (01) : 156 - 160
  • [5] LACTIC-ACIDOSIS COMPLICATING THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME
    CHATTHA, G
    ARIEFF, AI
    CUMMINGS, C
    TIERNEY, LM
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 118 (01) : 37 - 39
  • [6] CHEN CH, 1991, MOL PHARMACOL, V39, P625
  • [7] CELLULAR AND MOLECULE EVENTS LEADING TO MITOCHONDRIAL TOXICITY OF 1-(2-DEOXY-2-FLUORO-1-BETA-D-ARABINOFURANOSYL)-5-LODOURACIL IN HUMAN LIVER-CELLS
    CUI, LX
    YOON, SY
    SCHINAZI, RF
    SOMMADOSSI, JP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (02) : 555 - 563
  • [8] Riboflavin to treat nucleoside analogue-induced lactic acidosis
    Fouty, B
    Frerman, F
    Reves, R
    [J]. LANCET, 1998, 352 (9124) : 291 - 292
  • [9] HAVLIR D, 2000, 7 C RETR OPP INF
  • [10] MITOCHONDRIAL TOXICITY OF ANTIVIRAL DRUGS
    LEWIS, W
    DALAKAS, MC
    [J]. NATURE MEDICINE, 1995, 1 (05) : 417 - 422